The ASCO 2025 congress in Chicago, Illinois united the global Oncology community to discuss the latest breakthroughs in cancer research. APICES, as a CRO with 16 years of experience in Oncology clinical trials, we were honored to be part of this significant event, where our booth became a hub for sharing insights with researchers, clinicians, and industry leaders dedicated to advancing cancer care.
Clinical Trials at the Forefront of Innovation
A highlight of ASCO 2025 was the emphasis on how clinical trials are transforming Oncology. The congress showcased developments that underline the importance of well-designed trials in turning scientific discoveries into real-world treatments. We were excited to hear about upcoming studies focused on immunotherapy, targeted treatments, and precision medicine, all aimed at enhancing patient survival and quality of life.
Our Commitment to Oncology Trials
Reflecting on our journey as a CRO, we have facilitated trials that drive the development of new cancer therapies. Each trial represents a crucial step toward providing patients access to life-changing treatments.
With over 16 years of dedicated experience in Oncology trials, APICES has become a leader in cancer clinical research. Our extensive background allows us to navigate the complexities of clinical studies, driving innovation and improving patient outcomes. We pride ourselves on conducting rigorous and compliant trials, which has positioned us as a trusted partner in the clinical research community. As we continue to push the boundaries of Oncology, our commitment to excellence remains unwavering, ensuring that we contribute meaningfully to the development of new treatments for cancer patients.
Learning from ASCO 2025: What’s Next?
A key takeaway from ASCO 2025 is the shift from knowledge to real-world impact in oncology. Cross-sector collaboration is accelerating the translation of cutting-edge sciences like CAR-T cells and next-generation immunotherapies. We are eager to leverage our expertise to help bring these transformative therapies to clinical practice.
We look forward to seeing everyone at ASCO 2026, which will be held in Chicago, Illinois.
Unable to attend ASCO 2025? Contact us at [email protected] to discuss your Oncology clinical trials projects.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
